Cerenome (PSTV) Accounts Payables (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Accounts Payables of $6.2 million for Q1 2026, down 33.24% year-over-year from $9.2 million in Q1 2025, and up 4.0% quarter-over-quarter from $5.9 million in Q4 2025.
Cerenome (PSTV) Accounts Payables (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Accounts Payables for 17 consecutive years, with $6.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accounts Payables fell 33.24% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (down 33.24% YoY), while the FY2025 annual figure was $5.9 million, down 47.55% from the prior year.
- Accounts Payables grew to $6.2 million in Q1 2026 per PSTV's latest filing, from $5.9 million in the prior quarter.
- Across five years, Accounts Payables topped out at $11.6 million in Q3 2025 and bottomed at $3.2 million in Q1 2022.
- Historically, Accounts Payables has averaged $7.2 million across 5 years, with a median of $6.5 million in 2023.
- Annual changes were most pronounced in 2022 — Accounts Payables surged 288.13% — and 2025, when it plunged 47.55%.
- Plus Therapeutics' Accounts Payables stood at $10.1 million in 2022, then tumbled by 34.57% to $6.6 million in 2023, then surged by 70.23% to $11.3 million in 2024, then slumped by 47.55% to $5.9 million in 2025, then advanced by 4.0% to $6.2 million in 2026.
- Business Quant data shows PSTV's Accounts Payables at $6.2 million in Q1 2026, $5.9 million in Q4 2025, and $11.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 35.57 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 7.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.16 Mn |
| Dec 31, 2025 | 5.92 Mn |
| Sep 30, 2025 | 11.62 Mn |
| Jun 30, 2025 | 6.36 Mn |
| Mar 31, 2025 | 9.22 Mn |
| Dec 31, 2024 | 11.29 Mn |
| Sep 30, 2024 | 7.91 Mn |
| Jun 30, 2024 | 6.95 Mn |
| Mar 31, 2024 | 6.45 Mn |
| Dec 31, 2023 | 6.63 Mn |
| Sep 30, 2023 | 6.07 Mn |
| Jun 30, 2023 | 6.58 Mn |
| Mar 31, 2023 | 6.50 Mn |
| Dec 31, 2022 | 10.13 Mn |
| Sep 30, 2022 | 5.71 Mn |
| Jun 30, 2022 | 5.26 Mn |
| Mar 31, 2022 | 3.20 Mn |
| Dec 31, 2021 | 2.61 Mn |
| Sep 30, 2021 | 2.63 Mn |
| Jun 30, 2021 | 1.61 Mn |